Summary

Report Overview
The Global Topical Pain Relief Market reached US$ 10.5 billion in 2023 and is expected to reach US$ 15.77 billion by 2031, growing at a CAGR of 5.3% during the forecast period 2024-2031.
Topical pain refers to a type of pain or discomfort that is superficially felt in the skin or mucous membranes. Commonly, topical pain presents itself as localized pain with various causes. It can be brought about by common skin irritations like rashes, burns, or minor cuts and abrasions. They break the skin's usual function and thereby produce painful or uncomfortable sensations.
Infections are another common cause of topical pain. The most common viral infections, usually manifesting as painful sores of the skin or mucous membranes, include herpes simplex. Similarly, bacterial infections may lead to localized pain and swelling. Inflammation emanating from conditions such as dermatitis or arthritis can also serve as a source of topical pain through irritation of the skin and deeper tissues. Generally, topical pain is treated by applications of creams, ointments, or gels directly to the site of injury. They include analgesics that relieve pain directly, and anti-inflammatory agents that act in reducing swelling and irritation.
Market Dynamics: Drivers
Increasing prevalence of orthopedic diseases
The rising prevalence of orthopedic diseases propels the market growth. For instance, according to the Institute for Health Metrics and Evaluation, a new study projects nearly 1 billion people will be living with osteoarthritis, the most common form of arthritis, by 2050. Currently, 15% of individuals aged 30 and older experience osteoarthritis. Osteoarthritis increases with age. For ages 70+ years, the condition ranked seventh among causes for years lived with disability.
The most common spots for osteoarthritis are knees and hands. By 2050, osteoarthritis of the knee will increase by 75%, and osteoarthritis of the hand by 50%. Osteoarthritis impacts women more than men. The study found that cases increased rapidly over the past three decades because of three main factors: aging, population growth, and obesity. In 1990, 256 million people had osteoarthritis. By 2020, this number rose to 595 million people, which was a 132% increase from 1990. By 2050, this number is projected to approach the 1 billion mark. The most common areas for osteoarthritis are knees and hips. The most common areas for osteoarthritis are knees and hips.
Restraints
Factors such as side effects caused by pain relief medications and stringent regulatory requirements for the approval of new treatments are expected to hamper the market. In a few cases, side effects such as swelling or redness of skin or unusual pain appear at the site of application, and nausea is observed when these pain relief medications are applied.
Market Segment Analysis
The global topical pain relief market is segmented based on type, therapeutic class, formulation, distribution channel, and region.
The segment over-the-counter(OTC) pain relief accounted for approximately 48.5% of the global topical pain relief market share
The over-the-counter(OTC) pain relief segment is expected to hold the largest market share over the forecast period. In this segment, technological advancements would drive this market.
Over-the-counter (OTC) medicines are medicines that can be purchased without a prescription. They are used to treat a variety of symptoms and illnesses such as headaches, aches and pains, sore throat, nose congestion, fever, fungal infection, upset stomach, coughs, and colds.
For instance, in March 2023, AloeMD LLC launched Ultimate RepairX™ (URX). It is a topical pain relief medication with a patented 100% natural clinically proven anti-inflammatory pain relief cream that doesn’t mask muscle and tissue pain like other creams but stabilizes and restores tissue. The product was formulated by medical doctors after decades of research and utilizes a combination of powerful pharmaceutical-grade botanicals and a smart absorption delivery system. The patented matrix of bio-ceutical compounds is delivered directly into distressed tissue, working immediately to alleviate pain and inflammation, and working with the body to restore tissue naturally.
Market Geographical Analysis
North America accounted for approximately 43.6% of the global topical pain relief market share
North America region is expected to hold the largest market share over the forecast period. The rising incidence of orthopedic diseases, and technological advancements, in this region, help to propel the market.
For instance, according to an article published by HealthDay News in October 2023, arthritis is becoming a disease of the masses, striking 21% of U.S. adults, or over 53 million people. About 88% of all arthritis cases were adults aged 45 and up, while about 50% were working-age people ranging in age from 18 to 64. About 58% of people who have COPD have arthritis, as do 56% of those with dementia, 53% who have had a stroke, and 52% with heart disease. About 55% of adults with a disability have arthritis.
Moreover, according to the Osteoarthritis Action Alliance (OAAA), the CDC estimates that 1 in 5 (or 53.2 million) US adults have some form of arthritis. While there are estimated to be more than 100 types of arthritis, osteoarthritis (OA) is the most common form of arthritis, affecting 32.5 million US adults. 62% of individuals with osteoarthritis are women.
Market Segmentation
By Type
Over-the-counter (OTC) Pain Relief
Prescription Pain Relief Foscarnet
By Therapeutic Class
Opioids
Morphine
Hydrocodone
Fentanyl
Others
Non-opioids
Dexamethasone
Corticosteroids
Diclofenac
Others
By Formulation
Cream
Gel
Spray
Patch
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major global players in the global topical pain relief market include Johnson & Johnson Services Inc., GlaxoSmithKline Plc, Novartis AG, Pfizer Inc., Reckitt Benckiser Group Plc, Sun Pharmaceutical Industries Ltd., Endo International Plc, Teva Pharmaceutical Industries Ltd., Sanofi, Viatris Inc. among others.
Key Developments
In September 2024, Mankind Pharma announced its entry into the topical analgesic market through its consumer business division. The company is introducing Nimulid Strong, a revolutionary gel and spray formulation specifically designed to address neck pain, a condition that significantly impacts overall body function.
In April 2022, Jenburkt Wellness, the premium consumer-wellness division from the house of publicly listed organization Jenburkt Pharmaceuticals Ltd, announced the launch of Zixa Strong, a high-performing pain-relief range that delivers fast-acting and long-lasting relief from muscle and joint pains.
Why Purchase the Report?
To visualize the global topical pain relief market segmentation based on type, therapeutic class, formulation, distribution channel, and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development
Excel data sheet with numerous data points of global topical pain relief market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.
The global topical pain relief market report would provide approximately 51 tables, 54 figures, and 181 Pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Therapeutic Class
3.3. Snippet by Formulation
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Orthopedic Diseases
4.1.2. Restraints
4.1.2.1. Side Effects Caused due to the Medication
4.1.2.2. Stringent Regulatory Requirements
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. By Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
6.1.2. Market Attractiveness Index, By Type
6.2. Over-the-counter (OTC) Pain Relief*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Prescription Pain Relief
7. By Therapeutic Class
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Class
7.1.2. Market Attractiveness Index, By Therapeutic Class
7.2. Opioids*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Non-opioids
8. By Formulation
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Formulation
8.1.2. Market Attractiveness Index, By Formulation
8.2. Cream*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Gel
8.4. Spray
8.5. Patch
8.6. Others
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacy*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacy
9.4. Online Pharmacy
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Class
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Formulation
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. U.S.
10.2.7.2. Canada
10.2.7.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Class
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Formulation
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.7.1. Germany
10.3.7.2. UK
10.3.7.3. France
10.3.7.4. Italy
10.3.7.5. Spain
10.3.7.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Class
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Formulation
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. Brazil
10.4.7.2. Argentina
10.4.7.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Class
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Formulation
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.7.1. China
10.5.7.2. India
10.5.7.3. Japan
10.5.7.4. South Korea
10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Class
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Formulation
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Johnson & Johnson Services Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. GlaxoSmithKline Plc
12.3. Novartis AG
12.4. Pfizer Inc.
12.5. Reckitt Benckiser Group Plc
12.6. Sun Pharmaceutical Industries Ltd.
12.7. Endo International Plc
12.8. Teva Pharmaceutical Industries Ltd.
12.9. Sanofi
12.10. Viatris Inc. (*LIST NOT EXHAUSTIVE)
13. Appendix
13.1. About Us and Services
13.2. Contact Us